Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care provid...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Sulais, Eman, AlAmeel, Turki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966952/
https://www.ncbi.nlm.nih.gov/pubmed/32021084
http://dx.doi.org/10.2147/BTT.S236433
_version_ 1783488851118915584
author Al Sulais, Eman
AlAmeel, Turki
author_facet Al Sulais, Eman
AlAmeel, Turki
author_sort Al Sulais, Eman
collection PubMed
description Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients’ concerns.
format Online
Article
Text
id pubmed-6966952
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69669522020-02-04 Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease Al Sulais, Eman AlAmeel, Turki Biologics Review Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients’ concerns. Dove 2020-01-10 /pmc/articles/PMC6966952/ /pubmed/32021084 http://dx.doi.org/10.2147/BTT.S236433 Text en © 2020 Al Sulais and AlAmeel. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Al Sulais, Eman
AlAmeel, Turki
Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title_full Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title_fullStr Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title_full_unstemmed Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title_short Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
title_sort biosimilars to antitumor necrosis factor agents in inflammatory bowel disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966952/
https://www.ncbi.nlm.nih.gov/pubmed/32021084
http://dx.doi.org/10.2147/BTT.S236433
work_keys_str_mv AT alsulaiseman biosimilarstoantitumornecrosisfactoragentsininflammatoryboweldisease
AT alameelturki biosimilarstoantitumornecrosisfactoragentsininflammatoryboweldisease

Ejemplares similares